In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Exelon trades slightly above its fair value with a -4.4% implied downside, reflecting mixed signals from valuation methods, including a notably low DCF estimate versus high EV/EBITDA targets. Financial health scores indicate fair but constrained growth and liquidity, elevating risk. Monte Carlo analysis shows extreme volatility and high downside risk, highlighting potential for both significant gains and losses.